Investment Summary

Edmond de Rothschild Private Equity Invests In Chase Pharmaceuticals

On May 12, 2014, private equity firm Edmond de Rothschild Private Equity invested in life science company Chase Pharmaceuticals

Investment Highlights
  • This is Edmond de Rothschild Private Equity’s 6th transaction in the Life Science sector.
  • This is Edmond de Rothschild Private Equity’s 2nd transaction in the United States.
  • This is Edmond de Rothschild Private Equity’s 1st transaction in District of Columbia.
Investment Fate
  • Chase Pharmaceuticals was sold to a publicly-traded strategic buyer in 2016 for 125M USD.

Investment Summary

Date 2014-05-12
Target Chase Pharmaceuticals
Sector Life Science
Investor(s) Edmond de Rothschild Private Equity
Deal Type Venture

Target

Chase Pharmaceuticals

Washington, District of Columbia, United States
Chase Pharmaceuticals Corporation, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. Chase's development program, if successful, will profoundly improve the symptomatic treatment of Alzheimer's disease.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor
DESCRIPTION

Edmond de Rothschild Private Equity is the private equity arm of asset manager and financial services firm Edmond de Rothschild. The private equity group looks seeks buyout and expansion style investments and will consider opportunities across the world, including North America, Europe, and Africa. The Firm broadly invests in real estate, infrastructure projects, and directly in companies. Edmond de Rothschild Private Equity is based in Geneva, Switzerland.


DEAL STATS #
Overall 24 of 31
Sector: Life Science M&A 6 of 7
Type: Venture M&A Deals 5 of 5
State: District of Columbia M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2014 M&A 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-04-04 Genticel S.A.

Labège-Innopole, France

Genticel S.A. is a biotechnology company specialized in the development of a vaccine against infection responsible for uterin cancers. Genticel was formed in 2001 and is based in Labège-Innopole, France.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-01 Groupe ADF

Vitrolles, France

Groupe ADF is a provider of industrial engineering and maintenance services. It specializes in three business lines including engineering & expertise, the supply of production and testing equipment, and production & maintenance services. The company serves the Aeronautics, Space & Defense, Energy, and Oil & Gas sectors. Groupe ADF is based in Vitrolles, France.

Sell -